statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stock Radar: M&amp;M Financial, Biocon, Dr Reddys Labs, Sansera Engineering, Kalyan Jewellers in focus on Tuesday

Century Textiles, Suraj Estate Developers, Wipro, IFGL Refractories, Capacite Infraprojects, MOIL, Adani Power, Bharat Forge, 3i Infotech, and Jaiprakash Associates will also be in focus on Tuesday.

Trade Spotlight: How should you trade Bata, Divis Labs, Escorts, Mazagon Dock, HUDCO, Biocon, and others on Thursday?

Experts expect the Nifty 50 index to take support at the 22,600-22,500 zone, and above these levels, there is a possibility of a resumption of the upmove towards the 23,000 mark. However, below 22,500, a sharp downward move can't be ruled out.

Stock Radar: BHEL, PI Industries, Metropolis, Sheela Foam, PNC Infratech, Biocon in focus on Wednesday

Grasim Industries, Sun Pharma, Power Grid Corporation, Paytm, Nykaa, Ashoka Buildcon, Dhanlaxmi Bank, GE Power India, Gland Pharma, GMM Pfaudler, HEG, Jubilant FoodWorks, New India Assurance Company, and Unichem Laboratories will announce their March quarter earnings on May 22.

Biocon Q4 net profit down 56% at Rs 135.5 crore

Biocon Q4: The company's revenue from operations fell 15 percent to Rs 2947.3 crore from last year's Rs 2542.8 crore in the same period.

Biocon inks supply, distribution pact with Medix for chronic weight management drug in Mexico

Under the agreement with Medix, a specialty pharmaceutical firm, Biocon will be responsible for obtaining regulatory approval, manufacturing and supply of the drug, the company said in a statement.

Trade Spotlight | Your play for Biocon, Havells India, Engineers India today

Havells India, for instance, saw a breakout of its falling resistance trendline adjoining the highs of March 2 and April 8, and formed a big bullish candlestick pattern on the daily timeframe with healthy volumes.

Biocon inks licensing pact with Biomm for diabetes management drug Semaglutide in Brazil

Under the agreement, Biocon will handle the development, manufacturing, and supply of the diabetes management drug, while Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market

Biocon Q4 PAT may dip 192.8% YoY to Rs 67.1 cr: ICICI Securities

Net Sales are expected to increase by 3.5 percent Y-o-Y (down 1.2 percent Q-o-Q) to Rs 3,730.4 crore, according to ICICI Securities.

Biocon leads India push into weight loss drugs as patents lapse

The Bengaluru-based firm has scored an early win among its peers with the UK approval for the first generic version of liraglutide injectible, which is losing patent protection in November.

Biocon Biologics  signs 10-year supply deal with Eris Lifesciences for Rs 1242 crore

As part of the deal over 430 employees associated with the business are expected to transition to Eris

Biocon Ltd. is a holding company, which engages in the manufacture, research, and development of therapeutic drugs. It operates through the following segments: Small Molecules, Biologics, Branded Formulations, and Research Services. The Small Molecules segment manufactures spanning statins, immunosuppressants, antifungals, anti-obesity, anti-diabetics, ophthalmologicals, oncologicals, and urologicals etc. The Biologics segment provides Insulins and Analogs, biosimilar Monoclonal Antibodies (MAbs), and recombinant proteins The Branded Formulation segment consists of therapeutic areas of diabetology, oncology, immunology and critical care. The Research Services segment covers Syngene development platforms. The company was founded by Kiran Mazumdar-Shaw on November 29, 1978 and is headquartered in Bangalore, India.

Volume	9.11M
52-Wk High	376.80
52-Wk Low	217.50

BIOCON.NSE Biocon

About

Feed

News

Sentiment

Fundamentals